Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease. Supportive treatments, such as erythropoiesis-stimulating agents (ESAs), are commonly used in patients with low-risk MDS. This study aimed to retrospectively assess the impact of bone marrow Mothers against decapentaplegic...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2025-03-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/11564 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850030526026481664 |
|---|---|
| author | Bedrettin Orhan Hülya Öztürk Nazlıoğlu Oğuzhan Dik Büşra Gürbüz Vildan Özkocaman Tuba Ersal İbrahim Ethem Pınar Pınar Cumali Yalçın Yalçın Sinem Çubukçu Tuba Güllü Koca Fazıl Çağrı Hunutlu Şeyma Yavuz Rıdvan Ali Fahir Özkalemkaş |
| author_facet | Bedrettin Orhan Hülya Öztürk Nazlıoğlu Oğuzhan Dik Büşra Gürbüz Vildan Özkocaman Tuba Ersal İbrahim Ethem Pınar Pınar Cumali Yalçın Yalçın Sinem Çubukçu Tuba Güllü Koca Fazıl Çağrı Hunutlu Şeyma Yavuz Rıdvan Ali Fahir Özkalemkaş |
| author_sort | Bedrettin Orhan |
| collection | DOAJ |
| description |
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease. Supportive treatments, such as erythropoiesis-stimulating agents (ESAs), are commonly used in patients with low-risk MDS. This study aimed to retrospectively assess the impact of bone marrow Mothers against decapentaplegic homolog 7 (SMAD-7) and transforming growth factor beta 1 (TGF-β1) protein expression on prognosis and response to ESA treatment in patients with low-risk MDS. We retrospectively analyzed patients diagnosed with low-risk MDS at the adult hematology department of Bursa Uludağ University Hospital. A total of 56 patients classified as low or very low risk were included in the study. Immunohistochemical analysis of bone marrow specimens at diagnosis showed that only five patients (9.8%) exhibited low SMAD-7 staining, while 51 patients (90.2%) showed no staining. Regarding TGF-β1 staining, 18 patients (32.1%) demonstrated moderate to high staining, whereas 38 patients (67.9%) exhibited low (36/38) or no staining (2/38). A statistically significant correlation was found between TGF-β1 staining levels and ESA treatment administration (P = 0.011). Additionally, a significant relationship was observed between lower erythropoietin (EPO) levels and moderate to high TGF-β1 staining (P = 0.04). However, when TGF-β1 staining status was compared with first- and third-month treatment responses in patients receiving ESA therapy, no significant difference was detected between groups. These findings suggest that while TGF-β1 alone may not be sufficient to predict ESA treatment response, additional parameters related to the TGF-β/SMAD pathway should be considered. Strong TGF-β1 staining, alongside EPO levels, may influence the decision to initiate ESA therapy.
|
| format | Article |
| id | doaj-art-904bf3bf92fb4e4c84a58ba394b8638c |
| institution | DOAJ |
| issn | 2831-0896 2831-090X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj-art-904bf3bf92fb4e4c84a58ba394b8638c2025-08-20T02:59:12ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2025-03-0110.17305/bb.2025.11564Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndromeBedrettin Orhan0https://orcid.org/0000-0003-3970-2344Hülya Öztürk Nazlıoğlu1Oğuzhan Dik2https://orcid.org/0009-0006-3203-5568Büşra Gürbüz3Vildan Özkocaman4Tuba Ersal5İbrahim Ethem Pınar Pınar6https://orcid.org/0000-0001-9907-1498Cumali Yalçın Yalçın7https://orcid.org/0000-0002-5129-2977Sinem Çubukçu8Tuba Güllü Koca9Fazıl Çağrı Hunutlu10https://orcid.org/0000-0002-4991-9830Şeyma Yavuz11Rıdvan Ali12Fahir Özkalemkaş13Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDepartment of Pathology, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDepartment of Pathology, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDepartment of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, TürkiyeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, Türkiye Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease. Supportive treatments, such as erythropoiesis-stimulating agents (ESAs), are commonly used in patients with low-risk MDS. This study aimed to retrospectively assess the impact of bone marrow Mothers against decapentaplegic homolog 7 (SMAD-7) and transforming growth factor beta 1 (TGF-β1) protein expression on prognosis and response to ESA treatment in patients with low-risk MDS. We retrospectively analyzed patients diagnosed with low-risk MDS at the adult hematology department of Bursa Uludağ University Hospital. A total of 56 patients classified as low or very low risk were included in the study. Immunohistochemical analysis of bone marrow specimens at diagnosis showed that only five patients (9.8%) exhibited low SMAD-7 staining, while 51 patients (90.2%) showed no staining. Regarding TGF-β1 staining, 18 patients (32.1%) demonstrated moderate to high staining, whereas 38 patients (67.9%) exhibited low (36/38) or no staining (2/38). A statistically significant correlation was found between TGF-β1 staining levels and ESA treatment administration (P = 0.011). Additionally, a significant relationship was observed between lower erythropoietin (EPO) levels and moderate to high TGF-β1 staining (P = 0.04). However, when TGF-β1 staining status was compared with first- and third-month treatment responses in patients receiving ESA therapy, no significant difference was detected between groups. These findings suggest that while TGF-β1 alone may not be sufficient to predict ESA treatment response, additional parameters related to the TGF-β/SMAD pathway should be considered. Strong TGF-β1 staining, alongside EPO levels, may influence the decision to initiate ESA therapy. https://www.bjbms.org/ojs/index.php/bjbms/article/view/11564Myelodysplastic syndromeMDSMothers against decapentaplegic homolog 7SMAD-7Transforming Growth Factor Beta 1TGF-β1 |
| spellingShingle | Bedrettin Orhan Hülya Öztürk Nazlıoğlu Oğuzhan Dik Büşra Gürbüz Vildan Özkocaman Tuba Ersal İbrahim Ethem Pınar Pınar Cumali Yalçın Yalçın Sinem Çubukçu Tuba Güllü Koca Fazıl Çağrı Hunutlu Şeyma Yavuz Rıdvan Ali Fahir Özkalemkaş Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndrome Biomolecules & Biomedicine Myelodysplastic syndrome MDS Mothers against decapentaplegic homolog 7 SMAD-7 Transforming Growth Factor Beta 1 TGF-β1 |
| title | Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndrome |
| title_full | Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndrome |
| title_fullStr | Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndrome |
| title_full_unstemmed | Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndrome |
| title_short | Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndrome |
| title_sort | predictive value of tgf β1 and smad 7 expression at diagnosis for treatment response in low risk myelodysplastic syndrome |
| topic | Myelodysplastic syndrome MDS Mothers against decapentaplegic homolog 7 SMAD-7 Transforming Growth Factor Beta 1 TGF-β1 |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/11564 |
| work_keys_str_mv | AT bedrettinorhan predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT hulyaozturknazlıoglu predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT oguzhandik predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT busragurbuz predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT vildanozkocaman predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT tubaersal predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT ibrahimethempınarpınar predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT cumaliyalcınyalcın predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT sinemcubukcu predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT tubagullukoca predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT fazılcagrıhunutlu predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT seymayavuz predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT rıdvanali predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome AT fahirozkalemkas predictivevalueoftgfb1andsmad7expressionatdiagnosisfortreatmentresponseinlowriskmyelodysplasticsyndrome |